ISTH DIC subcommittee communication on anticoagulation in COVID-19
ISTH DIC subcommittee communication on anticoagulation in COVID-19
复制标题
DOI：
10.1111/jth.15004
复制
发表时间：
2020-09-01
影响因子：
10.4
通讯作者：
Levy, Jerrold H.
中科院分区：
文献类型：
--
作者：
Thachil, Jecko;Juffermans, Nicole P.;Levy, Jerrold H.
高凝是SARS-CoV-2感染的一种日益被认识到的并发症。因此，抗凝已成为COVID-19综合管理的重要组成部分。然而，在这一领域存在一些不确定因素，包括肝素的适当类型和剂量。此外，特殊的患者群体，包括那些高体重指数和肾功能受损的患者，需要特别考虑。虽然目前的证据仍然不足，但我们提供了一种实用的COVID-19抗凝治疗方法，但强调需要在该领域进行进一步的试验。
Hypercoagulability is an increasingly recognized complication of SARS-CoV-2 infection. As such, anticoagulation has become part and parcel of comprehensive COVID-19 management. However, several uncertainties exist in this area, including the appropriate type and dose of heparin. In addition, special patient populations, including those with high body mass index and renal impairment, require special consideration. Although the current evidence is still insufficient, we provide a pragmatic approach to anticoagulation in COVID-19, but stress the need for further trials in this area.